Noxopharm (ASX:NOX) DARRT-1 Clinical Results Presentation, December 2019, Sydney

Company Presentations

Noxopharm Limited (ASX:NOX) CEO & Founder Dr Graham Kelly provides a summary and latest updates for the DAART Program. University of Wollongong's Head of School & Dean of Medicine, Professor Paul de Souza analyses DAART-1 results and efficacy signals.

Agenda:

  • DARRT Program Summary
  • Study conclusions
  • Eligible patients
  • DARRT-1 Trial Design
  • DARRT-1 Results (Dr de Souza)
  • Unmet Clinical Need
  • Comparisons
  • DARRT-2/DARRT-3
  • Milestones Ahead
  • Recent M&A Activity

For more information, view the presentation by CEO & Founder Dr Graham Kelly and Head of School & Dean of Medicine, Professor Paul de Souza.